Organisation paid for research Program year 2025 Source: CMS Open Payments

Bradenton Research Center

Neither a doctor nor a teaching hospital

Research payments

$2,098,688

61 payments

Through program year 2025, Bradenton Research Center is reported as receiving $2,098,688 in research payments, across 61 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $158,380 5
2024 Research $104,729 3
2023 Research $165,523 4
2022 Research $765,769 21
2021 Research $566,177 14
2020 Research $273,986 5
2019 Research $64,124 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $1,004,573 26 payments
  2. Novartis Pharmaceuticals Corporation $608,569 14 payments
  3. Biogen, Inc. $252,178 8 payments
  4. Amgen Inc. $232,468 11 payments
  5. Shionogi Inc $900 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $982,275 25 payments
  2. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $543,859 9 payments
  3. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $174,341 2 payments
  4. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity $105,814 2 payments
  5. DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS $64,856 1 payment
  6. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $60,181 3 payments
  7. A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) $32,666 1 payment
  8. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $28,950 1 payment
  9. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $27,923 2 payments
  10. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $22,298 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record